Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $257.81M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 8.49M
Average 10.19M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Autolus Therapeutics plc NASDAQ:AUTL | $311.41M | $1.17 | Not rated | -1.4 | -15.50% |
Century Therapeutics, Inc. NASDAQ:IPSC | $298.77M | $1.65 | Not rated | -1.8 | +179.59% |
Precision BioSciences, Inc. NASDAQ:DTIL | $211.33M | $7.57 | Not rated | -1.9 | +35.06% |
Fate Therapeutics, Inc. NASDAQ:FATE | $149.20M | $1.28 | Not rated | -1.8 | +0.00% |
Cellectis S.A. NASDAQ:CLLS | $118.86M | $1.18 | Not rated | -4.6 | -74.21% |
Atara Biotherapeutics, Inc. NASDAQ:ATRA | $78.45M | $7.70 | Not rated | -14.7 | -51.71% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | $0.36 | Not rated | -1.1 | -73.83% |
Celularity Inc. NASDAQ:CELU | $20.45M | $0.63 | Not rated | -0.6 | +5.17% |
Continue the stock analysis
Jump to another research area for this company.